Tag: Investigational New Drug Application (IND)
FDA Accepts Investigational New Drug Application for Novel Peanut Allergy Therapy
The company, which is already in phase 2 clinical trials with a treatment for celiac disease, has announced the FDA has accepted their Investigational New Drug (IND) application for evaluation of CNP-201, A treatment for peanut allergy. that reduces the need for strict peanut avoidance and reduces the potentially fatal health risks associated with peanut allergy.
Aquestive Charts Ambitious Path Forward for Sublingual Emergency Epinephrine
Company updates the public on status of their candidate drug administered under the tongue.
Peanut Allergy Vaccine Takes Another Step with Biomarker Study
Study will help establish the starting dose of its vaccine candidate for a subsequent in-human phase I study.
Toothpaste Therapy for Food Allergies Takes Another Step Forward
FDA accepts IND application by Intrommune Therapeutics.
FDA Opens Door for Clinical Development of Aquestive Therapeutics Anaphylaxis Treatment
Emergency epinephrine candidate dissolves in the mouth.
Intrommune’s Food Allergy Toothpaste Therapy to Advance to Clinical Trials
See the interview with the CEO as well as a new video describing the therapy here.
Bryn Pharma Completes Dosing in Pivotal Clinical Trial Designed to Support...
Nasal Spray Product is Disruptive Innovation for People at Risk of Anaphylaxis.
Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate
AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
ConsortiaTX Awarded Exclusive License for Food Allergy Microbial Therapy
The company is developing therapies for food allergies based on bacteria found in the human gut microbiome.
Company Developing Peanut Immunotherapy Toothpaste Meets with FDA
"INT301 has the potential to be the first allergy immunotherapy treatment that easily integrates into a person’s daily routine."
